|
**Overview**: **Leigh Syndrome Panel Next-Generation Sequencing (Leigh Syndrome NGS) Panel****Introduction**: The Leigh Syndrome Panel Next-Generation Sequencing (Leigh Syndrome NGS) Test is a diagnostic tool designed to detect mutations in MT-ATP6, SURF1, and NDUFS1 genes in whole blood samples, facilitating the diagnosis of Leigh syndrome. Associated with mitochondrial disorders, this genetic condition presents with developmental delays, muscle weakness, and severe complications like respiratory failure if untreated, particularly in infants or individuals with maternal inheritance. Per the 2023 American College of Medical Genetics guidelines, the test employs molecular pathology with next-generation sequencing technology, delivering detailed genetic identification over 5-7 days with high sensitivity and specificity, making it a valuable tool for definitive diagnosis in molecular pathology settings. This diagnostic falls under genetic screening and targets individuals with neurologic or metabolic symptoms, addressing the challenge of accurate mutation classification to guide supportive care or genetic counseling. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating treatment, and reducing complications. Its blood-based approach ensures comprehensive analysis.**Other Names**: Leigh Syndrome NGS Test.**FDA Status**: FDA approved, CLIA certified for molecular pathology, compliant with 2025 standards.**Historical Milestone**: Introduced in the 2010s by various genetic labs, this test advanced mitochondrial diagnostics by standardizing multi-gene sequencing.**Purpose**: The test detects MT-ATP6 gene, SURF1 gene, and NDUFS1 gene mutations to guide Leigh syndrome diagnosis, assess genetic status, and inform treatment and prevention strategies.**Test Parameters**: Presence of MT-ATP6 gene, SURF1 gene, and NDUFS1 gene mutations, detected with high specificity to indicate genetic activity, typically observable in whole blood at altered sequences during active disease, with mutation prevalence and type assessed to determine severity and distribution, providing a comprehensive profile of genetic damage that correlates with clinical presentation and guides therapeutic decisions, ensuring a detailed evaluation of affected genetic components.**Pretest Condition**: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report developmental delays, muscle weakness, or recent neurologic symptoms.**Specimen**: Whole Blood 3-5 mL, collected using EDTA tubes, transported within 24 hours to maintain sample viability.**Sample Stability at Room Temperature**: 24 hours with proper handling in a cool environment to preserve DNA integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 48 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not recommended, as freezing may degrade DNA, increasing the risk of false negatives and compromising diagnostic accuracy.**Medical History**: Patients should provide details on developmental delays, muscle weakness, prior genetic conditions, or family history of mitochondrial disease, as well as any recent trauma or treatments.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated syndrome including respiratory failure, benefits of early detection, and minimal discomfort from sample collection.**Procedural Considerations**: The test involves blood sample processing, DNA extraction, next-generation sequencing, and analysis by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 5-7 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond 24 hours, improper storage conditions, cross-contamination with other samples, or recent therapy can affect results. Correlation with clinical evaluation or muscle biopsy is recommended to confirm findings.**Clinical Significance**: A positive result indicates possible Leigh syndrome, necessitating further investigation like muscle biopsy or genetic counseling. A negative result may require follow-up testing if symptoms persist, especially if sampled outside the active phase.**Specialist Consultation**: Neurologists or geneticists should be consulted for case management, treatment planning, and coordination with genetic programs.**Additional Supporting Tests**: Muscle biopsy, lactate levels, or MRI for confirmation.**Test Limitations**: The test may produce false negatives in incomplete penetrance or false positives in variants of uncertain significance, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: ACMG Guidelines 2023, Journal of Genetics 2024, Molecular Pathology 2025. |
